MUC1-targeted dendritic cell vaccine

The MUC1-targeted dendritic cell vaccine is an investigational cancer immunotherapy designed to stimulate the immune system to recognize and attack tumor cells expressing the mucin 1 (MUC1) antigen. This approach uses autologous or allogeneic dendritic cells that are loaded ex vivo with peptides or glycopeptides derived from the tumor-associated antigen MUC1, which is overexpressed and aberrantly glycosylated in many cancers including breast, lung, colon, prostate, and melanoma. The loaded dendritic cells are then administered back to the patient—typically via subcutaneous or intrapleural injection—to prime T-cell mediated anti-tumor immunity. Clinical studies have shown that this strategy can induce strong antigen-specific immune responses and has demonstrated signals of clinical efficacy such as reduced tumor burden and improved survival in patients with advanced cancers expressing MUC1[4][5][6]. The mechanism of action involves enhanced presentation of the immunogenic epitopes of hypoglycosylated MUC1 by activated dendritic cells to T lymphocytes, leading to a targeted cytotoxic response against cancer cells[2][4]. Various formulations exist (e.g., peptide-loaded DCs; adenoviral vector encoding human MUC-1), but all share this core principle.

Other names

MUC1 Dendritic Cell VaccineMUC-1 Dendritic Cell VaccineMUC 1 Dendritic Cell VaccineDC vaccine targeting MUC1dendritic cell-based immunotherapy targeting MUC1